TJ Kipps

475 total citations
18 papers, 378 citations indexed

About

TJ Kipps is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, TJ Kipps has authored 18 papers receiving a total of 378 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 9 papers in Immunology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in TJ Kipps's work include Chronic Lymphocytic Leukemia Research (15 papers), Immunodeficiency and Autoimmune Disorders (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). TJ Kipps is often cited by papers focused on Chronic Lymphocytic Leukemia Research (15 papers), Immunodeficiency and Autoimmune Disorders (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). TJ Kipps collaborates with scholars based in United States, Germany and Sweden. TJ Kipps's co-authors include DA Carson, PL Greenberg, Dieter Deforce, John C. Byrd, Anders Österborg, Danelle F. James, Laura Z. Rassenti, Jens Mayer, Stephan Stilgenbauer and Hua Mu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Haematologica.

In The Last Decade

TJ Kipps

17 papers receiving 368 citations

Peers

TJ Kipps
D G Oscier United Kingdom
L Perdiguer Spain
Lucia Savino Italy
Panagiotis Baliakas Sweden
M. Angelopoulou Greece
Kate E Hodgson Spain
S V Payne United Kingdom
E Moreau Belgium
Massimo Drosera Italy
BM Wilkes United States
D G Oscier United Kingdom
TJ Kipps
Citations per year, relative to TJ Kipps TJ Kipps (= 1×) peers D G Oscier

Countries citing papers authored by TJ Kipps

Since Specialization
Citations

This map shows the geographic impact of TJ Kipps's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by TJ Kipps with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites TJ Kipps more than expected).

Fields of papers citing papers by TJ Kipps

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by TJ Kipps. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by TJ Kipps. The network helps show where TJ Kipps may publish in the future.

Co-authorship network of co-authors of TJ Kipps

This figure shows the co-authorship network connecting the top 25 collaborators of TJ Kipps. A scholar is included among the top collaborators of TJ Kipps based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with TJ Kipps. TJ Kipps is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Sharman, Jeffrey P., Steven Coutré, Richard R. Furman, et al.. (2014). PP-054 EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Leukemia Research. 38. S44–S45. 2 indexed citations
2.
James, Danelle F., Lillian Werner, William G. Wierda, et al.. (2010). Lenalidomide and rituximab for the initial treatment of chronic lymphocytic leukemia: Report of an ongoing study.. Journal of Clinical Oncology. 28(15_suppl). 6583–6583. 3 indexed citations
3.
Tsimberidou, Apostolia M., William G. Wierda, Xavier C. Badoux, et al.. (2010). Evaluation of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in aggressive chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS).. Journal of Clinical Oncology. 28(15_suppl). 6521–6521. 2 indexed citations
4.
Kipps, TJ, et al.. (2009). Circulating ofatumumab concentrations correlate with responseand progression-free survival in fludarabine-refractory chroniclymphocytic leukemia. Haematologica. 1 indexed citations
5.
Kipps, TJ, Anders Österborg, Jens Mayer, et al.. (2009). Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy. Journal of Clinical Oncology. 27(15_suppl). 7043–7043. 4 indexed citations
6.
Wierda, William G., TJ Kipps, Jens Mayer, et al.. (2009). Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 27(15_suppl). 7044–7044. 3 indexed citations
7.
James, Danelle F., et al.. (2008). Primary chronic lymphocytic leukemia (CLL) cells survival support from NLC and SDF-1a (CXCL-12) in vitro and the effect of lenalidomide (LEN). Journal of Clinical Oncology. 26(15_suppl). 7070–7070. 1 indexed citations
8.
Byrd, John C., Ian W. Flinn, TJ Kipps, et al.. (2008). Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study. Journal of Clinical Oncology. 26(15_suppl). 7003–7003. 6 indexed citations
9.
Pathan, Nazima, TJ Kipps, Alessandra Cesano, et al.. (2008). Correlation of clinical activity of lumiliximab in combination with FCR and ZAP 70 expression on B-cell chronic lymphocytic leukemia cells. Journal of Clinical Oncology. 26(15_suppl). 7073–7073.
10.
Shustik, Chaim, Robert Turner, P. Desjardins, et al.. (2005). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Phase II Study of Oral Fludarabine in Untreated B-Cell Chronic Lymphocytic Leukemia.. Blood. 106(11). 2977–2977. 3 indexed citations
11.
Kipps, TJ, William G. Wierda, Michael J. Keating, et al.. (2005). A phase I/II study of Xcellerated T Cells in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology. 23(16_suppl). 2511–2511. 1 indexed citations
12.
Chu, Peter, et al.. (2000). Characterization of CD4 cytotoxic T cells specific for autologous chronic lymphocytic leukemia B cells. Blood. 96. 677–677. 2 indexed citations
13.
Kipps, TJ & DA Carson. (1993). Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood. 81(10). 2475–2487. 142 indexed citations
14.
Kipps, TJ & DA Carson. (1993). Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood. 81(10). 2475–2487. 121 indexed citations
15.
16.
17.
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D G Oscier Breakdown of academic impact, for papers by L Perdiguer Breakdown of academic impact, for papers by Lucia Savino Breakdown of academic impact, for papers by Panagiotis Baliakas Breakdown of academic impact, for papers by M. Angelopoulou Breakdown of academic impact, for papers by Kate E Hodgson Breakdown of academic impact, for papers by S V Payne Breakdown of academic impact, for papers by E Moreau Breakdown of academic impact, for papers by Massimo Drosera Breakdown of academic impact, for papers by BM Wilkes
Rankless by CCL
2026